Compare ITP & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | HCWB |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.7M |
| IPO Year | 2020 | 2021 |
| Metric | ITP | HCWB |
|---|---|---|
| Price | $0.19 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 168.1K | 97.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,837,943.00 | $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.22 |
| 52 Week High | $1.00 | $17.80 |
| Indicator | ITP | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 36.86 |
| Support Level | $0.17 | N/A |
| Resistance Level | $0.22 | $1.35 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 43.30 | 54.76 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.